MYD88 and Alzheimer disease: In view of the present results, the development and validation of new approaches for the treatment of AD is recommended, such as the possible use of antagonists/inhibitors of the TLR pathway to preferentially limit the association of TLRs with MyD88 and reduce NFκB activity and/or CKs and ChKs secretion.